
CABAZITAXEL
API impurity is used in pharmaceutical applications.Benefits:Semi-synthetic derivative of a natural taxoidIt is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapyIt was developed by Sanofi-Aventis and approved by the U.S. FDA for the treatment of hormone-refractory prostate cancer on June 17, 2010




